You are currently viewing a new version of our website. To view the old version click .

Vaccines, Volume 13, Issue 7

July 2025 - 114 articles

Cover Story: HIV remains a global health challenge despite significant advancements in antiretroviral therapy and prevention strategies. Developing a safe and effective vaccine that protects people worldwide has been a major goal, yet the genetic variability and rapid mutation rate of the virus continue to pose substantial challenges. Over 35 years of HIV vaccine research have yielded a mix of discouraging trial results and invaluable scientific insights that suggest an HIV vaccine will likely not resemble any traditional vaccine, as it may require novel antigen designs and delivery methods and a combination of approaches. Ongoing research remains active and continues to explore novel approaches, and these recent advances offer hope for progress in the fight against HIV. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (114)

  • Article
  • Open Access
1 Citations
1,304 Views
18 Pages

19 July 2025

Background: Measuring frequencies of antigen-specific memory B cells (Bmem), their immunoglobulin (Ig) class and subclass usage, cross-reactivity, and affinity can provide insights into the efficacy of future antibody responses in case of antigen re-...

  • Article
  • Open Access
1,135 Views
12 Pages

mRNA-LNP Vaccines Targeting SmpA-PLD and OmpK-Omp22 Induce Protective Immunity Against Acinetobacter baumannii

  • Cong Liu,
  • Xingyun Wang,
  • Yueling Zheng,
  • Xingyue Gao,
  • Jiahui Jin,
  • Xing Cheng,
  • Yunjiao He and
  • Peng George Wang

19 July 2025

Background: Acinetobacter baumannii (A. baumannii) has emerged as a critical human pathogen, causing high mortality rates among hospitalized patients and frequently triggering nosocomial outbreaks. The increasing prevalence of multidrug-resistant (MD...

  • Article
  • Open Access
1,432 Views
16 Pages

Evaluating Free PPV23 Vaccination for the Elderly in Nanning, China: A Cost-Effectiveness Analysis

  • Zhengqin Su,
  • Linlin Deng,
  • Dan Luo,
  • Jianying Ren,
  • Xiaozhen Shen,
  • Wenjie Liang,
  • Haibin Wei,
  • Xiong Zou,
  • Zhongyou Li and
  • Hai Li

18 July 2025

Background: This study aims to evaluate the cost-effectiveness of providing the 23-valent pneumococcal polysaccharide vaccine (PPV23) free of charge versus self-paying vaccination among adults aged 60 years and older in Nanning, Guangxi, China. Metho...

  • Article
  • Open Access
1,420 Views
27 Pages

Immunogenicity of DNA, mRNA and Subunit Vaccines Against Beak and Feather Disease Virus

  • Buyani Ndlovu,
  • Albertha R. van Zyl,
  • Dirk Verwoerd,
  • Edward P. Rybicki and
  • Inga I. Hitzeroth

17 July 2025

Background/Objectives: Beak and feather disease virus (BFDV) is the causative agent of psittacine beak and feather disease (PBFD), affecting psittacine birds. There is currently no commercial vaccine or treatment for this disease. This study develope...

  • Review
  • Open Access
3 Citations
1,456 Views
22 Pages

Adaptation of the Vaccine Prophylaxis Strategy to Variants of the SARS-CoV-2 Virus

  • Sofia M. Gulova,
  • Uliana S. Veselkina and
  • Irina V. Astrakhantseva

17 July 2025

The emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus closely related to SARS-CoV and officially known as Betacoronavirus pandemicum precipitated a substantial surge in vaccine development that culminated during...

  • Brief Report
  • Open Access
954 Views
6 Pages

17 July 2025

Our study demonstrates that IVIG lots manufactured in 2023–2024 contain neutralizing antibodies against circulating Omicron variants, including KP.3 and XEC. These variants are resistant to all convalescent plasma and IVIG preparations produced...

  • Article
  • Open Access
1 Citations
952 Views
13 Pages

Effects of Canine IL-12 on the Immune Response Against the Canine Parvovirus VP2 Protein

  • Shiyan Wang,
  • Wenjie Jiao,
  • Dannan Zhao,
  • Yuzhu Gong,
  • Jingying Ni,
  • Huawei Wu,
  • Jige Du,
  • Tuanjie Wang and
  • Chunsheng Yin

16 July 2025

Background: Canine parvovirus (CPV) is a highly pathogenic virus that predominantly affects puppies, with mortality rates exceeding 70%. Although commercial multivalent live attenuated vaccines (MLV) are widely employed, their efficacy is often compr...

  • Communication
  • Open Access
1,381 Views
11 Pages

XBB.1.5 COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel Disease

  • Simon Woelfel,
  • Joel Dütschler,
  • Daniel Junker,
  • Marius König,
  • Georg Leinenkugel,
  • Claudia Krieger,
  • Samuel Truniger,
  • Annett Franke,
  • Seraina Koller and
  • Katline Metzger-Peter
  • + 10 authors

16 July 2025

Background: Mucosal immunity plays a pivotal role in preventing infections with SARS-CoV-2. While COVID-19 mRNA vaccines induce robust systemic immune responses in patients with inflammatory bowel disease (IBD), little is known about their efficacy i...

  • Article
  • Open Access
1,739 Views
26 Pages

Optimization of YF17D-Vectored Zika Vaccine Production by Employing Small-Molecule Viral Sensitizers to Enhance Yields

  • Sven Göbel,
  • Tilia Zinnecker,
  • Ingo Jordan,
  • Volker Sandig,
  • Andrea Vervoort,
  • Jondavid de Jong,
  • Jean-Simon Diallo,
  • Peter Satzer,
  • Manfred Satzer and
  • Kai Dallmeier
  • + 2 authors

16 July 2025

Background: Modern viral vector production needs to consider process intensification for higher yields from smaller production volumes. However, innate antiviral immunity triggered in the producer cell may limit virus replication. While commonly used...

  • Article
  • Open Access
1 Citations
1,038 Views
11 Pages

A Cross-Sectional Survey to Identify Current Pneumococcal Vaccination Practices and Barriers in Rural Community Pharmacies

  • Ashley H. Chinchilla,
  • Tyler C. Melton,
  • Salisa C. Westrick,
  • Tessa J. Hastings,
  • Leticia Vieira,
  • Grace T. Marley and
  • Delesha M. Carpenter

16 July 2025

Background: Pneumococcal vaccination rates in the United States (US) remain suboptimal, especially for adults aged 19 to 64 with high-risk medical conditions. Community-pharmacy-based immunization services increase vaccine access, particularly in rur...

of 12

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Vaccines - ISSN 2076-393X